Bexitrol F 50/250 Maxhaler
by Beximco Pharmaceuticals Ltd.
৳1120.00
The ACME Laboratories Ltd.
Salmeterol + Fluticasone Propionate
patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2-agonist or patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.
Salmeterol is a selective long-acting (12 hours) beta-2-adrenoceptor agonist with a long side chain that binds to the exo-site of the receptor.
Inhalation Aerosol:
Inhalation Powder in Capsule (For Asthma):
Inhalation Powder in Capsule (For COPD): Salmeterol 50 µg & Fluticasone 250 µg twice daily (morning and evening, approximately 12 hours apart). Rinsing the mouth after each inhalation is advised.
Inhalation Powder in Maxhaler (For Asthma): This is a moulded plastic device containing a foil strip with 60 regularly placed blisters containing pre-dispensed inhalation powder. Patients should be made aware that Maxhaler must be used daily for optimum benefit, even when asymptomatic.
Adults and Adolescents (12 years and older)-
Children (4 years and older)-
Inhalation Powder in Maxhaler (For COPD):
Using an Inhaler seems simple, but most patients do not know how to use it in the right way. If the Inhaler is used in the wrong way, less medicine can reach the lungs. Correct and regular use of the Inhaler will prevent or lessen the severity of asthma attacks.
Following simple steps can help to use Inhaler effectively (According to "National Asthma Guidelines for Medical Practitioners" published by Asthma Association):
Instructions for Cleaning Inhaler: Clean your Inhaler at least once a week. Remove canister and rinse the plastic actuator and cap in warm water but do not put the metal canister into water. Dry the actuator and cap thoroughly and gently replace the metal canister into the actuator with a twisting motion. Put the cap on the mouthpiece.
Both non-selective and selective β-blockers should be avoided in patients with asthma unless there are compelling reasons for their use.
This is contraindicated in patients with a history of hypersensitivity to any of the ingredients.
As this preparation contains Salmeterol and Fluticasone Propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no incidence of additional adverse events following concurrent administration of the two compounds.
Administration of drugs during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus or child. There is insufficient experience of the use of Salmeterol Xinafoate and Fluticasone Propionate in human pregnancy and lactation. There are no data available for human breast milk.
Consideration should be given to additional corticosteroid therapies, and to including administration of antibiotics if an infection is present.
Long-acting selective β-adrenoceptor stimulants, Respiratory corticosteroids
Pressurized canister, do not puncture, break or incinerate even when apparently empty. Avoid storage in direct sunlight or heat. Store below 30°C. Keep away from eyes.
ACME Laboratories Ltd.